We are finishing eval for a model with better capabilities in this regard and I'm excited to test this case within this one to see if this behavior is resolved

"makes sense" and "desired behavior" are of course different things. I think this is a great example of how ambiguity in query can trip us up where better self reflection after citation retrieval could help. Basically, which interpretation of the Q makes most sense AFTER we pull references.

There should be a share icon in top right. We make you attest that there is no PHI in the query before you make it public (see below) then you should be able to copy link

Yeah I think there is something going on with being confused whether "dual" refers to ETA and ETB or refers to ETA and angiotensin. At the end of the answer you posted it used dual to talk about ETA and ETB. Thanks for posting.

No this isn't right.... I see now from your answer it was sending you experimental ET_A antagonists... Ok. Well we will dig and figure out what's going on

Ok I THINK I know what's going on. I believe it's interpreting "dual endothelin" and a request for a inhibitor of both ETA and ETB, but sparsentan only blocks ETA. If I can get the raw query, we will dive into it on our quality team and figure it out

Are there any dual endothelin and angiotensin inhibitors | OpenEvidence Yes, there are dual endothelin and angiotensin inhibitors, with sparsentan being the first FDA-approved agent in this class. Sparsentan is a single-molecule, orally active antagonist that selectively ...

Would you mind sharing the link to the answer. I cant replicate. Always looking to improve
www.openevidence.com/ask/21690269...

EP10 Travis Zack MD, PhD and Varun Mangalick BS, Open Evidence STAT AI: An Emergency Medicine Podcast · Episode

@travizack.bsky.social and Varun from OE talk AI and the future of medical information on the STAT-AI podcast:
open.spotify.com/episode/121y...

We have a new deepconsult feature that is a bit more directed at literature review.

Happy first day!
To all interns, residents, fellows, and new attendings.

We are building specialty specific learning communities at OE. If you are interested in joining peers and learning together with Openevidence, shoot us an email at md_community@openevidence.com

Your gift can ignite discovery and inspire cures What are you passionate about? Unlocking the brain’s mysteries? Battling health inequity? Donate to UCSF today, and together we will build a healthier tomorrow.

Dr. Atul Butte was laid to rest today. His large shoulders and larger vision have been foundational to all AI can and will accomplish in healthcare.
His family is requesting those interested to please consider supporting research on mpnst here: giving.ucsf.edu/fund/maligna...

Selfie of Lancet Senior Executive Editor, Vania Wisdom, and Acting Deputy Editor at The Lancet Oncology, Kat Gourd. Both are Lancet Oncology Ambassadors, attending the American Society of Clinical Oncology (ASCO) conference in Chicago, USA.

👋 Our editors are on-site at #ASCO25, Chicago.

We’re excited to be part of this gathering of global cancer experts—come & meet us.

‘Contact the Editor’ details below, in-thread 🧵 @ascocancer.bsky.social

Hello from the City of Lakes! We’re thrilled to welcome thousands of members of the ob-gyn community to the 2025 Annual Clinical & Scientific Meeting. From the heart of the Midwest, we’re kicking off a weekend of connection, learning, and inspiration. Share the excitement using #ACOG2025!

OpenEvidence The leading medical information platform.

As for the safety, I asked @openevidence.bsky.social which is a chatbot trained on the professional medical literature. The current thinking is that it is not ready for primetime. www.openevidence.com/ask/2ca4fd30...

Welcome JAMA!!

OpenEvidence - CME has arrived on OpenEvidence CAMBRIDGE, MA, April 2, 2025 – We are thrilled to announce that CME is now available for free on OpenEvidence! Verified NPI users can now earn AMA PRA Category 1 Credits™.

we are now offering free CME credits just by OE in yuour normal practice:
www.openevidence.com/announcement...

I don't know... How do you feel :)

Congratulations 🎉 excited to welcome them to UCSF family

So thrilled to welcome this extraordinary group of 64 young physicians to @UCSF and @UCSFimresidency. A great day!

(UCPC=UCSF Health-based primary care program; SFGH=San Francisco General-based primary care; PSTP=physician-scientist training program) @UCSFIMChiefs @UCSFDOM

OpenEvidence - OpenEvidence and NEJM Group, publisher of the New England Journal of Medicine, sign content agreement: Clinicians using OpenEvidence benefit from content sourced from NEJM Group journal... CAMBRIDGE, MA, February 19, 2025 – OpenEvidence, the fastest-growing platform for doctors, has signed a multi-year content agreement with NEJM Group, publisher of the New England Journal of Medicine (...

www.openevidence.com/announcement...

EP10 Travis Zack MD, PhD and Varun Mangalick BS, Open Evidence STAT AI: An Emergency Medicine Podcast · Episode

@travizack.bsky.social and Varun from OE talk AI and the future of medical information on the STAT-AI podcast:
open.spotify.com/episode/121y...

www.openevidence.com/ask/88013027...

OpenEvidence - What is the evidence for emapalumab in hlh The evidence for emapalumab in hemophagocytic lymphohistiocytosis (HLH) is based on clinical studies demonstrating its efficacy in patients with primary HLH who have refractory, recurrent, or progress...

That's really amazing! Hope this helps
www.openevidence.com/ask/47b4d834...

Some background on current limited TX options:
www.openevidence.com/ask/a94c01ac...
However, there is a recently opened clinical trial for this rare disease
clinicaltrials.gov/study/NCT061...
@jerryclee.bsky.social

Some mechanistic background:
www.openevidence.com/ask/07ad3d33...

A short review of where we were at prior to this trial
www.openevidence.com/ask/1e95f6d9...

The New England Journal of Medicine CRISPR-Based Therapy for Hereditary Angioedema A PLAIN LANGUAGE SUMMARY Illustration of a patient with hereditary angioedema and NTLA-2002, a nonviral gene-editing therapy based on CRISPRCas9, for treatment. Read the full Plain Language Summary at NEJM.org.

In a new phase 2 trial, researchers evaluated the efficacy of a gene-editing therapy, NTLA-2002, in preventing angioedema attacks in patients with hereditary angioedema. Full trial results and Plain Language Summary: nej.md/4heR7hT

#MedSky #Oncology

www.openevidence.com/ask/55b54926...

As a primary care doctor & clinical informatician, I love using @openevidence.bsky.social during my clinic visits to review latest guidelines with patients & sources.

I strongly believe this practice helps build stronger therapeutic relationship with the doctor + AI assisted CDS. #CI=AI

Thanks so much for the shoutout. Ask for a patient summary. We will provide the information at an appropriate and inclusive reading level and can accommodate many languages